Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Trial Profile

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Ilodecakin (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTIST 1; Sequoia
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 09 Oct 2017 According to an ARMO BioSciences media release, Joseph Leveque, M.D. will lead this trial.
    • 20 Apr 2017 According to an ARMO BioSciences media release, results from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 29 Mar 2017 According to an ARMO BioSciences media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top